Core Viewpoint - Pacira BioSciences, Inc. is facing a class action securities lawsuit due to alleged securities fraud that has significantly impacted its stock price following the invalidation of a key patent [1][2]. Group 1: Lawsuit Details - The class action lawsuit aims to recover losses for investors affected by alleged securities fraud between August 2, 2023, and August 8, 2024 [1]. - On August 9, 2024, Pacira announced that its U.S. Patent No. 11,033,495, crucial for its product Exparel, was deemed invalid, leading to concerns about the validity of other patents and potential market competition [2]. - Following the patent invalidation announcement, Pacira's stock plummeted from $22.36 per share on August 8, 2024, to a low of $11.70 per share on August 9, 2024, marking a decline of over 47% in one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until March 14, 2025, to request appointment as lead plaintiff in the lawsuit [3]. - Participation in the lawsuit does not require any out-of-pocket costs or fees for class members [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4].

Core Viewpoint - Pacira BioSciences, Inc. faces significant legal challenges following the invalidation of its key patent, which could lead to increased competition and financial losses for the company [1]. Summary by Relevant Sections Legal Issues - Pacira's U.S. Patent No. 11,033,495, crucial for its product Exparel, was ruled invalid by the court, impacting approximately 80% of the company's revenue [1]. - The invalidation raises concerns about the validity of other patents held by Pacira, potentially allowing more generic competitors to enter the market [1]. Stock Performance - Following the announcement of the patent ruling, Pacira's stock price plummeted from $22.36 per share on August 8, 2024, to a low of $11.70 per share on August 9, 2024, marking a decline of over 47% in just one day [1]. Shareholder Actions - Shareholders who purchased shares during the class period from August 2, 2023, to August 8, 2024, are encouraged to register for a class action lawsuit, with a deadline for lead plaintiff appointment set for March 14, 2025 [2]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's progress [2].

NEW YORK, Feb. 11, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Pacira BioSciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Pacira investors who were adversely affected by alleged securities fraud between August 2, 2023 and August 8, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/pacira-biosciences-inc-lawsui ...

NEW YORK, Feb. 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX).Shareholders who purchased shares of PCRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/pacira-biosciences-inc-loss-submission-form/?id=127847&from=4CLASS PERIOD: Augus ...

NEW YORK, Feb. 7, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Pacira BioSciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Pacira investors who were adversely affected by alleged securities fraud between August 2, 2023 and August 8, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit ...

Core Insights - Pacira BioSciences, Inc. has granted inducement awards to 15 new employees as part of its Amended and Restated 2014 Inducement Plan to encourage their employment with the company [1] - The inducement awards for new Chief Commercial Officer Brendan Teehan include a non-qualified stock option for 99,500 shares and a restricted stock unit award for 54,000 shares, both vesting over a period of time [2] - Chief Business Officer Krys Corbett received similar inducement awards, including a non-qualified stock option for 88,400 shares and a restricted stock unit award for 46,000 shares, also with a vesting schedule [3] - Additional awards were granted to four other employees for a total of 20,600 stock options and to 13 employees for 45,400 restricted stock units, all with a 10-year term and a four-year vesting schedule [4] - The vesting of these equity awards is contingent upon the employees' continued employment with Pacira [5] Company Overview - Pacira specializes in innovative, non-opioid pain therapies, with three commercial-stage products: EXPAREL, ZILRETTA, and ioveraº, aimed at transforming patient care [6] - EXPAREL is a long-acting local analgesic for postsurgical pain management, ZILRETTA is an extended-release injection for osteoarthritis knee pain, and ioveraº is a device for drug-free pain control [6] - The company is also developing PCRX-201, a novel gene therapy targeting prevalent diseases like osteoarthritis [6]

SAN DIEGO, Feb. 5, 2025 /PRNewswire/ -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Pacira BioSciences, Inc. (NASDAQ: PCRX) securities between August 2, 2023 and August 8, 2024. Pacira is an American pharmaceutical company committed to developing and providing non-opioid pan management and regenerative health solutions.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350 ...

Core Insights - Pacira BioSciences, Inc. (PCRX) is identified as a potential stock pick due to a recent "golden cross" event, indicating a bullish trend from a technical perspective [1][4] - The golden cross occurs when a stock's 50-day simple moving average surpasses its 200-day simple moving average, suggesting a strong breakout potential [2] - PCRX has experienced a significant price increase of 42.4% over the past four weeks, further supporting the bullish outlook [4] Technical Analysis - A golden cross is characterized by three stages: the stock price bottoms out, the shorter moving average crosses above the longer moving average, and the stock maintains upward momentum [3] - The golden cross is contrasted with a death cross, which signals potential bearish movement [3] Earnings Outlook - The earnings outlook for PCRX is positive, with no downward revisions in earnings estimates over the past two months and two upward revisions, leading to an increase in the Zacks Consensus Estimate [4] - The current Zacks Rank for PCRX is 3 (Hold), indicating potential for a breakout [4] Investment Consideration - Investors are encouraged to consider adding PCRX to their watchlist due to the significant technical indicator and the positive movement in earnings estimates [5]

Group 1 - A class action lawsuit has been filed against Pacira Biosciences, Inc. concerning allegations of securities fraud and unlawful business practices by the company and its officers [2][3]. - Investors who purchased Pacira securities during the Class Period have until March 14, 2025, to request appointment as Lead Plaintiff [2]. - On August 9, 2024, Pacira's stock price dropped by $10.66 per share, or 47.67%, closing at $11.70 per share following the invalidation of its '495 patent for Exparel by the U.S. District Court [3]. Group 2 - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for class members [4].

Core Viewpoint - Pacira (PCRX) is positioned well to continue its trend of beating earnings estimates, supported by a solid history of performance and favorable earnings estimates [1][3]. Earnings Performance - In the most recent quarter, Pacira reported earnings of $0.79 per share, exceeding the expected $0.72 per share, resulting in a surprise of 9.72% [2]. - For the previous quarter, Pacira's earnings were $0.89 per share against an expectation of $0.73 per share, leading to a surprise of 21.92% [2]. Earnings Estimates - There has been a positive shift in earnings estimates for Pacira, with a current Earnings ESP (Expected Surprise Prediction) of +3.55%, indicating increased analyst optimism regarding its near-term earnings potential [3][6]. - The combination of a positive Earnings ESP and a Zacks Rank of 2 (Buy) suggests a strong likelihood of another earnings beat [6]. Predictive Metrics - Stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise [4]. - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions [5].